Comparative Effects of Local Denosumab and Recombinant Human Growth Hormone on Periodontal Remodeling in Experimental Periodontitis.
Denosumab and rhGH show potential for periodontal regeneration, but further human studies are needed to confirm their clinical applicability.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study compared the effects of local denosumab and recombinant human growth hormone on periodontal remodeling in experimental periodontitis in rabbits. Denosumab preserved alveolar bone height and density better than rhGH, while rhGH promoted greater new bone formation. Both treatments downregulated osteoclastogenesis-related gene expression.
Abstract
<h4>Background</h4>Periodontal regeneration remains challenging because conventional therapy does not predictably restore lost periodontal tissues. This study compared the periodontal remodeling responses associated with locally administered denosumab (DNS) and recombinant human growth hormone (rhGH) in experimental periodontitis.<h4>Materials and methods</h4>Twenty-four male New Zealand rabbits were randomly assigned to four groups: control, periodontitis (PDitis), PDitis treated with DNS, and PDitis treated with rhGH. Experimental periodontitis was induced by ligature placement and repeated inoculation with Porphyromonas gingivalis. Following disease induction, locally delivered DNS (3 mg) or rhGH (4 IU) gels were administered twice weekly for four weeks. Periodontal remodeling was evaluated using cone-beam computed tomography (CBCT), histological and histomorphometric analyses, and quantitative real-time polymerase chain reaction (qRT-PCR) assessment of bone remodeling-related genes.<h4>Results</h4>Both DNS and rhGH improved periodontal healing compared with untreated periodontitis. DNS demonstrated greater preservation of alveolar bone height (facial bone height: 11.97 ± 0.05 mm vs. 9.96 ± 0.06 mm for rhGH and 9.00 ± 0.17 mm for PDitis; P = 0.004) and higher facial bone density (898.47 ± 9.95 vs. 708.34 ± 9.83 and 728.90 ± 6.08, respectively; P = 0.004). Histomorphometric analysis showed the greatest new bone formation in the rhGH group, with facial and lingual new bone fractions of 74.44 ± 16.80% and 64.78 ± 6.38%, respectively (P = 0.005 and P < 0.001). Both therapies significantly downregulated osteoclastogenesis-related gene expression, with DNS producing greater suppression of RANKL, NFATc1, ACP-5, and Ctsk than rhGH.<h4>Conclusions</h4>Within the limitations of this experimental study, DNS and rhGH were associated with distinct periodontal remodeling phenotypes in experimental periodontitis. DNS predominantly demonstrated an anti-resorptive remodeling profile characterized by preservation of mineralized bone architecture, whereas rhGH promoted a more anabolic high-turnover remodeling response associated with active new bone formation. These findings support the translational potential of locally delivered biologically targeted therapies as adjunctive approaches for periodontal regeneration.
Background
Periodontal regeneration is a significant challenge in dental medicine, as conventional therapies often fail to restore lost periodontal tissues effectively. This study addresses the need for improved treatment strategies by comparing the effects of denosumab and recombinant human growth hormone on periodontal remodeling in an animal model. Understanding these effects could inform future therapeutic approaches for periodontal disease.
Methods
The study was conducted on 24 male New Zealand rabbits, divided into four groups: control, periodontitis, periodontitis treated with denosumab, and periodontitis treated with rhGH. Periodontitis was induced using ligature placement and Porphyromonas gingivalis inoculation. Treatments involved local administration of 3 mg denosumab or 4 IU rhGH gels twice weekly for four weeks. Outcomes were assessed using CBCT, histological analyses, and qRT-PCR of bone remodeling-related genes.
Results
Denosumab preserved alveolar bone height and density more effectively than rhGH, with significant differences in facial bone height (11.97 ± 0.05 mm vs. 9.96 ± 0.06 mm, P = 0.004) and density (898.47 ± 9.95 vs. 708.34 ± 9.83, P = 0.004). RhGH led to greater new bone formation, with facial and lingual new bone fractions of 74.44 ± 16.80% and 64.78 ± 6.38%, respectively. Both treatments significantly downregulated osteoclastogenesis-related gene expression, with denosumab showing greater suppression of specific genes.
Interpretation
The study suggests that denosumab and rhGH have distinct effects on periodontal remodeling, with denosumab showing stronger anti-resorptive properties and rhGH promoting anabolic bone formation. While these findings are promising, the clinical relevance is limited by the animal model and short duration. Further research in humans is necessary to determine the translational potential of these therapies.
Key findings
- Facial bone height: 11.97 ± 0.05 mm for DNS vs. 9.96 ± 0.06 mm for rhGH, P = 0.004.
- Facial bone density: 898.47 ± 9.95 for DNS vs. 708.34 ± 9.83 for rhGH, P = 0.004.
- New bone formation: 74.44 ± 16.80% for rhGH facial bone, P = 0.005.
- New bone formation: 64.78 ± 6.38% for rhGH lingual bone, P < 0.001.
- Greater suppression of RANKL, NFATc1, ACP-5, and Ctsk by DNS.
Limitations
- small n=24
- animal model (rabbits)
- 4-week follow-up
- no human data